Digital ulcers (DU) are a common manifestation of systemic sclerosis (SSc) and occur at a variety of locations including the fingertips and over the extensor aspects of the hands.
INTRODUCTION
Digital ulcers (DUs) are common in patients with SSc and are responsible for much of the pain and disability associated with the disease. Despite current treatments to prevent (e.g. endothelial receptor-1 antagonists and phosphodiesterase type-5 inhibitors)(1,2) and treat DUs(3), recurrent DUs remain a major clinical burden in many patients with SSc(4-6). Recent prospective (collected over two years) data from the DUO (Digital Ulcer Outcome) registry revealed that over half of patients had either 'recurrent' DUs (more than 2 episodes) or 'chronic' DUs (present at every clinic visit) (46.2 % and 11.2%, respectively)(6).
DUs commonly occur on the fingertip and over the extensor aspects of the hands, particularly overlying the small joints of the hands. Amanzi et al (7) reported that (out of 792 DUs) fingertip DUs were commoner than extensor DUs (55% vs 31%). Whereas, in a prospective study over 12 months, the prevalence of both fingertip and extensor DUs was 6%, and both types of DU were equally disabling(5). DUs less commonly occur at other sites of the hands, including at the base of the nail and on the lateral aspects of the digits. DUs can also occur in relation to underlying subcutaneous calcinosis.
At present, fingertip DUs are generally believed to be ischaemic in aetiology, whereas, extensor aspect DUs are thought to occur due to recurrent microtrauma and increased skin tension from tissue fibrosis, often at sites of contracture. Little (if anything) is known about the pathophysiology of DUs which occur at other sites of the hands. It has been postulated that calcinosis could be related to SSc-related microangiopathy (8) , which could therefore also be implicated in calcinosis-associated DUs.
Another key issue operationally is that recent clinical trials of drug therapies for SSc-associated vasculopathy (1,2,9,10) have specifically excluded extensor aspect DUs, on the basis that these are not considered 'ischaemic' in aetiology, and therefore not likely to benefit from vasoactive drug therapies. However, if non-fingertip DUs also have a potentially reversible ischaemic component, then this would strongly warrant inclusion of these neglected DU types in the design of future SSc clinical trials.
The emerging evidence base to support an ischaemic drive to DUs in SSc shall now be discussed under the headings: 'microvascular imaging', 'structural' and 'functional microvascular disease', 'macrovascular involvement' and 'vascular associates'. It is important to highlight that these headings are arbitrary, and interlinked. Another important point is that many 'DU associations' have been examined for either 'any' (including extensor) DUs or for solely fingertip DUs. Therefore, it is not always possible when reviewing previous research studies to separate out the associations between the degree of SSc-related vascular disease and the individual subtypes of DUs. When reviewing the previous studies, where possible, we will describe which type(s) of DUs are being discussed.
MICROVASCULAR IMAGING
Both fingertip and extensor DUs have been shown by objective microvascular (laser Doppler and speckle) imaging to be relatively ischaemic compared to surrounding non-ulcerated skin (11, 12) , with a reduction in ischaemia observed with DU healing (11, 12) . Mechanical factors such as skin stretching over extensor surfaces may also be relevant and lead to further compromise at these sites. An example of laser Doppler imaging of both a fingertip and extensor DU is provided in Figure 1 . There is often a relative hyperaemia of the skin immediately surrounding the ischaemic DU centre (12, 13) , the aetiology of which at present is unclear, and this could be important in DU healing. In a recent double-blind, crossover, placebo controlled study of the vasodilator glyceryl trinitrate (GTN), applied topically as ointment directly to SSc-related DUs, GTN resulted in a significant increase in perfusion to the ischaemic centre (and also to a lesser extent to the surrounding tissue), with a similar response observed with both fingertip and extensor aspect DUs (13) .
STUCTURAL MICROVASCULAR DISEASE
Nailfold capillary abnormalities have been reported by several authors to be highly predictive of future DUs in patients with SSc(14-16). In a multicentre, prospective cohort study which included 486 patients with SSc and a history of DUs, the number of capillaries in the middle finger of the non-dominant hand (odds ratio of 0.84) was one of the three strongest predictors of future DUs, along with number of DUs and the presence critical digital ischaemia at baseline (16) . We have previously described that the capillaries (as assessed by videocapillaroscopy) of the skin immediately adjacent to both fingertip and extensor DUs are abnormal, with areas of capillary enlargement and neoangiogenesis, suggesting that SSc-associated microangiopathy contributes to both types of DU (17) .
FUNCTIONAL VASCULAR DISEASE
Functional microvascular disease has been associated with DUs. Blaise et al (18) reported that in patients with SSc the digital thermal hyperaemia pattern (an index of vascular function) is predictive of DU. In our retrospective study which included 138 patients (69 in each group), we assessed whether abnormal thermography (defined as a temperature gradient between the fingers and dorsum of the hand of >1°C at 30 O C) was associated with DU development (19) . 
MACROVASCULAR INVOLVEMENT
An increased prevalence of macrovascular disease has been reported in patients with SSc (20) , although this remains a controversial topic. Macrovascular disease has been reported to be both associated (increased renal artery stiffness) (21) and not associated (aortic stiffness) with DU development (22) . Proximal (large) vessel disease is an important consideration in clinical practice and likely reduces hand perfusion globally predisposing to DUs. In particular, selective involvement of the ulnar artery has been reported in patients with SSc(23), and has been found to be associated with the development of any DU (including fingertip, extensor and calcinosisassociated) DUs (24) . In a recent prospective study which included 55 patients with SSc and 19 healthy controls, the occurrence of new ischaemic (defined as occurring on the fingertip) DUs during one year of follow was associated (odds ratio) with both ulnar artery occlusion (8.73) and pathological finger pulp blood flow (11.20) (25) . Furthermore, in the multivariate analysis, the combination of both ulnar artery occlusion and pathological finger pulp blood flow was strongly associated with DU occurrence (7.45). Furthermore, a severe obliterative vasculopathy of the digital arteries has been reported in SSc (26) . Digital artery involvement could be an important contributor to the development of different types of DUs in SSc, through a generalised reduction in digital perfusion, on a background of a progressive microangiopathy.
VASCULAR ASSOCIATES
A number of vascular associates (both increased and lower risk) of DUs have been proposed in SSc, as described in a recent systematic review (27) . Examples of associates with an increased risk of DUs include increased circulating levels of endothelin-1 and autoantibodies toward endothelin receptor A (28, 29) , and increased vascular endothelial growth factor (28) . At present the evidence base for vascular associates of specific DUs subtypes is limited and requires further research.
THE RELIABILITY OF DU GRADING
This is a major concern in SSc clinical trials relating to digital vasculopathy. The overall reliability of rheumatologists with an interest in SSc (and therefore most likely to participate in clinical trials) is only poor to moderate at best (30) . In a recent web-based study which 
RESEARCH AGENDA
There are several key issues that need be addressed in relation to DU disease and clinical trial design. Firstly, the ischaemic aetiology to the development of DUs must be further explored, and whether this differs between different types of DUs. Secondly, as extensor DUs contribute to morbidity they should be assessed in clinical trials, and these should be documented separately, to see whether their response to treatment differs from fingertip DUs. Thirdly, what is the role of non-invasive imaging in both the prediction and monitoring of DU disease in SSc, including in future clinical trials? Fourthly, the contributory role of ischaemia on other ulcer cofactors (e.g. calcinosis and infection) should be explored, as these could also be modulated by vascular therapies. Finally, work is needed to improve the reliability of rheumatologists grading all types of DUs as an outcome measure in clinical trials.
CONCLUSION
In conclusion, we propose that all DUs in SSc could share a potentially reversible ischaemic component. If ischaemia contributes to the development and/or persistence of extensor as well as fingertip DUs, then extensor DUs could also benefit treatment with vasoactive drug therapies. Future research is needed to further understand the aetiology and treatment response of all SSc-related DUs, the role for non-invasive imaging in clinical trials, and to improve the reliability of DU grading as an outcome measure for future studies. With the emerging evidence base we strongly encourage the SSc international community to include all DUs in the design of future clinical trials.
